These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 15758787)

  • 1. Economic costs of benign prostatic hyperplasia in the private sector.
    Saigal CS; Joyce G
    J Urol; 2005 Apr; 173(4):1309-13. PubMed ID: 15758787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic consequences of irritable bowel syndrome: a US employer perspective.
    Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
    Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population.
    Shah M; Butler M; Bramley T; Curtice TG; Fine S
    Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database.
    Joish VN; Donaldson G; Stockdale W; Oderda GM; Crawley J; Sasane R; Joshua-Gotlib S; Brixner DI
    Curr Med Res Opin; 2005 Apr; 21(4):535-44. PubMed ID: 15899102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.
    Chang S; Long SR; Kutikova L; Bowman L; Finley D; Crown WH; Bennett CL
    J Clin Oncol; 2004 Sep; 22(17):3524-30. PubMed ID: 15337801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of treatment strategies for benign prostatic hyperplasia--is medical therapy more costly in the long run?
    Saigal CS; Movassaghi M; Pace J; Joyce G;
    J Urol; 2007 Apr; 177(4):1463-7; discussion 1467. PubMed ID: 17382755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
    Sasser AC; Rousculp MD; Birnbaum HG; Oster EF; Lufkin E; Mallet D
    Womens Health Issues; 2005; 15(3):97-108. PubMed ID: 15894195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.
    Ivanova JI; Birnbaum HG; Kidolezi Y; Qiu Y; Mallett D; Caleo S
    Epilepsia; 2010 May; 51(5):838-44. PubMed ID: 20002150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of work-related injuries in insured workplaces in Lebanon.
    Fayad R; Nuwayhid I; Tamim H; Kassak K; Khogali M
    Bull World Health Organ; 2003; 81(7):509-16. PubMed ID: 12973643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare expenditures for privately insured people with cystic fibrosis.
    Ouyang L; Grosse SD; Amendah DD; Schechter MS
    Pediatr Pulmonol; 2009 Oct; 44(10):989-96. PubMed ID: 19768806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urologic diseases in America project: benign prostatic hyperplasia.
    Wei JT; Calhoun E; Jacobsen SJ
    J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of psoriasis on health care costs and patient work loss.
    Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G
    J Am Acad Dermatol; 2008 Nov; 59(5):772-80. PubMed ID: 19119095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The annual impact of seasonal influenza in the US: measuring disease burden and costs.
    Molinari NA; Ortega-Sanchez IR; Messonnier ML; Thompson WW; Wortley PM; Weintraub E; Bridges CB
    Vaccine; 2007 Jun; 25(27):5086-96. PubMed ID: 17544181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
    Wu EQ; Birnbaum HG; Mareva M; Tuttle E; Castor AR; Jackman W; Ruskin J
    Curr Med Res Opin; 2005 Oct; 21(10):1693-9. PubMed ID: 16238910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and indirect costs associated with Dupuytren's contracture.
    Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
    J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia.
    Black L; Naslund MJ; Gilbert TD; Davis EA; Ollendorf DA
    Am J Manag Care; 2006 Mar; 12(4 Suppl):S99-S110. PubMed ID: 16551208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Private health insurance plans in 1976: an evaluation.
    Smith Carroll M
    Soc Secur Bull; 1978 Sep; 41(9):3-16. PubMed ID: 102042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia.
    Chirikos TN; Sanford E
    J Urol; 1996 Apr; 155(4):1311-6. PubMed ID: 8632563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.